Jim Cramer endorses
Danaher Corporation (DHR) as an important position, amidst growing interest from multiple investment management firms including International Assets Investment Management LLC and Private Advisor Group LLC. Despite recent underperformance in the market,
Danaher's Q3 2024 results indicate resilience and robust business strength.
Hedge funds have rallied around the stock. Key metrics in their earnings report exceeded Wall Street estimates with an
adjusted EPS of $1 and net earnings of
$818 Million. Factors fueling billionaire interest include prospects in
cancer research and success spearheaded by
subsidiary Cepheid. Heightened market visibility led KeyBanc to raise their stock target. Amidst cautiousness and perceived headwinds, analysts recommend retention of Danaher stocks due to forecasted
business strength and
growth visibility. Danaher's Q3 earnings were boosted by
bioprocessing order growth. Despite a cut in price target, Danaher remains optimistic about
business strength and stands by its
annual guidance. The corporation confirms Q3 and full-year guidance for 2024. Several analyst ratings recommend holding or overweighting Danaher stocks, with Q3 earnings beating estimates and indicating a strong
profits uptick.
Danaher Corporation DHR News Analytics from Wed, 24 Apr 2024 07:00:00 GMT to Sat, 26 Oct 2024 08:33:17 GMT -
Rating 6
- Innovation 5
- Rumor 3
